Abstract: There is provided a method of diagnosing a medical state associated with a neuro-psychiatric disorder in a subject, comprising: receiving EEG datasets from EEG electrodes monitoring a head of the subject, computing events for the EEG datasets, clustering the events into clusters, computing a p-adic representation of the clusters, extracting a p-adic topology from the p-adic representation of the clusters, computing a personal universal dendrogramic holographic signature (PUDHS) of the p-acid topology relative to a personalized threshold that separates between a relative large distance between events and a relatively small distance between events, the PUDHS denoting number of events below the personalized threshold, and diagnosing the medical state associated with the neuro-psychiatric disorder according to the PUDHS relative to a medical threshold that separates between presence of the medical state and non-presence of the medical state.

Abstract: A system which can be used for carrying out a method for determining an efficacy of a transcranial magnetic stimulation (TMS) treatment, including: delivering TMS to a patient using a TMS protocol in a TMS treatment session; recording EEG signals before and after the delivering during the treatment session; recording EEG signals after completion of the treatment session; analyzing the recorded EEG signals to generate values of one or more EEG parameters; determining an acute effect and an intermediate effect of the TMS protocol on a brain state of the patient based on a change in values of the one or more EEG parameters; determining an efficacy of the TMS protocol based on the determined acute effect and the intermediate effect.

Abstract: Methods and systems for predicting the onset and progression of neurodegenerative diseases using blood test data and machine learning models are disclosed. The method involves receiving blood test values for a target subject over a previous time period, extracting features from the blood test data, and applying a trained predictive model to compute a risk score indicating the probability of developing a neurodegenerative disease. The system includes a processor that executes code to perform the method and can be implemented as a standalone application, cloud-based service, or integrated with healthcare systems. The predictive models are trained using supervised learning on labeled data and can include statistical models or machine learning algorithms. The systems and methods enable early detection of neurodegenerative diseases, personalized risk prediction, and integration with existing healthcare infrastructure. By leveraging blood test data and machine learning techniques, patient outcomes may be improved.

Abstract: Disclosed herein is a multi-modal sensor system, including a wearable device configured to receive signals relating to a swallowing process of a subject, the wearable device including one or more surface Electromyograph sensors configured to receive signals relating to electrical potential in muscles of the throat, one or more bio-impedance sensors, one or more memories, one or more processors configured to operate one or more sensors of the wearable device, synchronize the signals to one or more predetermined events to generate a synchronization feature, receive the signals as a first diagnostic data set, analyze the first diagnostic data set, assess, based on the analysis, the swallowing process of the subject to yield an assessment output, and present the assessment output and determine a bio-impedance signal.

Abstract: Using microstate data to evaluate Alzheimer's disease including dementia and/or mild cognitive impairment and/or depression and optionally provide treatment based on the diagnosis and/or modify treatment and/or diagnosis based on response to treatment, optionally as measured using microstate data. In one example, the method includes analyzing EEG data to generate one or more EEG parameter; and generating a risk for one or both of depression and MCI (mild cognitive impairment) based on said one or more EEG parameters. Optionally, the disease comprises MCI. Optionally, the disease comprises depression. Optionally, the one or more EEG parameter comprises a microstate-derived parameter. Optionally, the one or more EEG parameter comprises a microstate duration derived parameter.

Abstract: A method comprises: for each specific medical intervention and/or respective clinical outcome: accessing a respective specific priority list of a respective sub-set of subjects scheduled in a prioritized sequence for treatment and/or evaluation, creating a respective specific training dataset that includes data extracted from EMRs of the respective sub-set of subjects labelled with the specific priority list, and training a respective specific machine learning model on the respective specific training dataset for generating an outcome of a respective specific priority list of a sub-set of subjects for prioritized evaluation and/or treatment, in response to an input of data extracted from EMR of the sub-set of subjects, accessing a combined prioritization component for generating an outcome of a combined priority list of subjects for prioritized evaluation and/or treatment in response to an input of outcomes of the specific machine learning models, and providing the specific models and the combined prioritizat

Abstract: A method of treating an inflammatory disease in a subject in need thereof is provided. The method comprising administering to the subject a therapeutically effective amount of a liquid chromatography fraction of a cannabis extract comprising at least 75% tetrahydrocannabinolic acid (THCA), wherein the fraction comprises cannabis derived active ingredients other than the THCA.

Abstract: There is provided a computer implemented method of diagnosing a medical state associated with a neuro-psychiatric disorder in a subject, comprising: receiving a plurality of EEG datasets, each respective EEG dataset from a respective EEG electrode of a plurality of EEG electrodes monitoring a head of the subject, clustering the plurality of EEG datasets into a plurality of clusters, computing a p-adic representation of the plurality of clusters, extracting a quantum potential value from p-adic representation of the plurality of clusters, and diagnosing the medical state associated with the neuro-psychiatric disorder according to the quantum potential relative to a threshold that separates between presence of the medical state and non-presence of the medical state.

Abstract: A method of assessing a subject including: measuring a plurality of respirations of the subject; determining one or more respiration parameter from the plurality of respirations; and determining, using the one or more respiration parameter, one or more of: a state of consciousness of the subject; and a prognosis of the subject.

Abstract: Embodiments pertain to ureteral stents for treatment of partial or full ureteral occlusion by bridging one or more ureteral occlusions, where each stent includes a tubular portion, a first spout portion and a second spout portion. The stent may have one or more tapered edges by having the smallest diameter of the first and/or the second spout portion smaller than the largest diameter of the tubular portion, and/or be of an overall length allowing the ureteral stent to be completely located within a patient's ureter once deployed therein.

Abstract: A method of predicting an analyte level comprises receiving a time-ordered series of levels of the analyte, monitored over a time-period; feeding a trained neural network procedure with the monitored levels; and displaying, based on an output received from the procedure, a predicted level of the analyte in a future time. The procedure can comprise a plurality of layers, wherein for at least one pair of layers, a number of inter-layer connections within the pair is higher for later monitored levels than for earlier monitored levels.

Abstract: According to some embodiments there is provided a wearable device for breast screening, comprising: at least one breast-contacting member shaped to contact a surface of a breast, the member comprising an array of force applying units and an array of sensors configured for sensing at least one parameter in response to force applied by the force applying units; the force applying units and the sensors disposed on or within the breast-contacting member and positioned to contact a surface of the breast; a memory storing one or more patterns suitable to detect a lump underlying the surface; wherein the pattern comprises a sequence of forces that vary spatially and/or vary in time; a controller configured for: reading data from the memory to control application of force; communicating with the sensors to receive signals associated with the at least one parameter sensed in response to the application of force; and to process the received signals to detect a lump.

Abstract: A method of treating a malignant disease in a subject in need thereof is provided. The method comprising administering to the subject a therapeutically effective amount of a first liquid chromatography fraction of a cannabis extract comprising at least 75% tetrahydrocannabinolic acid (THCA), and a therapeutically effective amount of a second liquid chromatography fraction of a cannabis extract comprising at least 75% cannabigerolic acid (CBGA), wherein the first liquid chromatography fraction comprises cannabis derived active ingredients other than the THCA, and the second liquid chromatography fraction comprises cannabis derived active ingredients other than the CBGA, thereby treating the malignant disease in the subject.

Abstract: Compositions and methods for the treatment of cutaneous T cell lymphoma (CTCL) are provided. The compositions and uses thereof comprise cannabinoids.

Abstract: A method for evaluating a treatment for a brain condition, including: extracting one or more microstate parameter values from at least one EEG signal that was measured after the treatment; and evaluating at least one parameter of the treatment based on the one or more microstate parameter values.

Abstract: According to some embodiments there is provided an anastomosis device configured to reduce leakage, comprising: a first set of rings sized to be positioned at a first tissue wall; a second set of rings sized to be positioned at a second tissue wall adjacent the first tissue wall; and an element configured to draw the ring sets towards each other; wherein each set of rings comprises an inner ring, an outer ring, and a coupling for aligning the inner and outer rings with respect to each other; wherein the inner ring applies a first pressure onto the tissue wall which is sufficient to gradually form a passage between the first and second tissue walls; and the outer ring applies a second pressure onto the tissue wall, the second pressure applied radially outwardly relative to the first pressure, the second pressure sufficient to reduce leakage in a vicinity of the passage.

Abstract: Described herein is the correlation between miR-451 expression and the increased benefit of a treatment modality of solid tumors that effects miR-451 modulated metabolic pathways. Such modalities include NAMPT inhibitors and/or PARP inhibitors. Also described herein are methods for treatment of solid tumors that include determining whether treatment of the tumor would benefit from inhibition of NAMPT and/or PARP and if so, treating the patient afflicted with the tumor with NAMPT and/or PARP inhibitors.

Abstract: Using microstate data to evaluate Alzheimer's disease including dementia and/or mild cognitive impairment and/or depression and optionally provide treatment based on the diagnosis and/or modify treatment and/or diagnosis based on response to treatment, optionally as measured using microstate data. In one example, the method includes analyzing EEG data to generate one or more EEG parameter; and generating a risk for one or both of depression and MCI (mild cognitive impairment) based on said one or more EEG parameters. Optionally, the disease comprises MCI. Optionally, the disease comprises depression. Optionally, the one or more EEG parameter comprises a microstate-derived parameter. Optionally, the one or more EEG parameter comprises a microstate duration derived parameter.

Abstract: A method of treating an inflammatory disease in a subject in need thereof is provided. The method comprising administering to the subject a therapeutically effective amount of a liquid chromatography fraction of a cannabis extract comprising at least 75% tetrahydrocannabinolic acid (THCA), wherein the fraction comprises cannabis derived active ingredients other than the THCA.

Abstract: A method for evaluating a treatment for a brain condition, including: extracting one or more microstate parameter values from at least one EEG signal that was measured after the treatment; evaluating at least one parameter of the treatment based on the one or more microstate parameter values.